From persistent nausea to fluctuating blood sugar levels, the symptoms of gastroparesis can vary in severity and frequency
However, the states Medicaid program doesnt cover Wegovy, glucagon-like peptide-1 receptor agonists, or GLP-1, drugs in doses meant for treating weight loss specifically
This means they cannot model the blood-brain barrier, develop necrotic cores during long-term culture, and cannot replicate how peripheral immune cells travel into the brain a central feature of TBM pathology
The FDA prescribing information for Mounjaro and Zepbound does not highlight arthralgia as a common adverse reaction, and joint inflammation is not identified as a known pharmacologic effect of GIP or GLP-1 receptor activation
Once shortages develop, they can last years
In the first month I only lost 2 pounds but with continued use I believe I will lose at least 15% of my total weight